<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599811426261</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599811426261</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Otology and Neurotology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Protective Effect of Erdosteine against Cisplatin-Induced Ototoxicity in a Guinea Pig Model</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Waissbluth</surname><given-names>Sofia</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811426261">1</xref>
<xref ref-type="aff" rid="aff2-0194599811426261">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dupuis</surname><given-names>Isabelle</given-names></name>
<xref ref-type="aff" rid="aff1-0194599811426261">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Daniel</surname><given-names>Sam J.</given-names></name>
<degrees>MD, MSc, FRCSC</degrees>
<xref ref-type="aff" rid="aff2-0194599811426261">2</xref>
<xref ref-type="aff" rid="aff3-0194599811426261">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599811426261"><label>1</label>McGill University, Montreal, Quebec, Canada</aff>
<aff id="aff2-0194599811426261"><label>2</label>McGill Auditory Sciences Laboratory, The Montreal Children’s Hospital, Montreal, Quebec, Canada</aff>
<aff id="aff3-0194599811426261"><label>3</label>Department of Otolaryngology, The Montreal Children’s Hospital, Montreal, Quebec, Canada</aff>
<author-notes>
<corresp id="corresp1-0194599811426261">Sam J. Daniel, MD, MSc, FRCSC, The Montreal Children’s Hospital, 2300 Rue Tupper, Rm B-240, Montreal, QC, Canada H3H 1P3 Email: <email>sam.daniel@muhc.mcgill.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>146</volume>
<issue>4</issue>
<fpage>627</fpage>
<lpage>632</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>6</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>9</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<p><italic>Objective</italic>. Cisplatin is a commonly used chemotherapeutic agent. One of its major dose-limiting side effects is ototoxicity. No treatment has yet been approved for this condition. The objective of this study was to determine the potential protective effect of a systemic administration of erdosteine against cisplatin-induced ototoxicity.</p>
<p><italic>Study Design</italic>. A prospective controlled trial conducted in an animal model.</p>
<p><italic>Setting</italic>. Animal care research facilities of The Montreal Children’s Hospital Research Institute.</p>
<p><italic>Subjects and Methods</italic>. A total of 27 guinea pigs were assigned to 4 groups, each receiving a different concentration of intraperitoneal erdosteine: group 1 (control group; n = 9) did not receive erdosteine, group 2 (n = 6) received 100 mg/kg/d, group 3 (n = 6) received 200 mg/kg/d, and group 4 (n = 6) received 500 mg/kg/d. The animals in the experimental groups received the erdosteine injection daily for 4 days. All of the animals received 12 mg/kg of intraperitoneal cisplatin. Auditory brainstem response threshold shifts were measured at 4 frequencies (8, 16, 20, and 25 kHz) for all groups. Scanning electron microscopy and outer hair cell counts were performed to assess the protective effect of erdosteine.</p>
<p><italic>Results</italic>. Significant protection was observed in groups 3 and 4 at 25 kHz. These findings are supported by outer hair cell counts by scanning electron microscopy.</p>
<p><italic>Conclusion</italic>. A systemic administration of erdosteine appears to provide an otoprotective effect at high frequencies for cisplatin-induced ototoxicity.</p>
</abstract>
<kwd-group>
<kwd>Erdosteine</kwd>
<kwd>cisplatin</kwd>
<kwd>cisplatinum</kwd>
<kwd>ototoxicity</kwd>
<kwd>antioxidant</kwd>
<kwd>hearing loss</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Cisplatin is a commonly used chemotherapeutic agent for various forms of cancers. Its clinical use has been limited by a variety of side effects including ototoxicity. Cisplatin causes dose-related, cumulative, progressive, and irreversible sensorineural hearing loss, which leads to a decreased quality of life.<sup><xref ref-type="bibr" rid="bibr1-0194599811426261">1</xref></sup> Damage to inner-ear structures begins at the basal turn of the cochlea, hence affecting high-frequency hearing primarily, which then progresses to the low-frequency areas.<sup><xref ref-type="bibr" rid="bibr2-0194599811426261">2</xref></sup></p>
<p>Reactive oxygen species have been shown to be implicated in the process of apoptosis caused by cisplatin in cochlear structures.<sup><xref ref-type="bibr" rid="bibr3-0194599811426261">3</xref></sup> Cisplatin administration in vivo has been shown to deplete cochleae of glutathione, an endogenous antioxidant, and decrease the activity of antioxidant enzymes in the inner ear such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase.<sup><xref ref-type="bibr" rid="bibr4-0194599811426261">4</xref></sup> As a result, reactive oxygen species, superoxide, and hydrogen peroxide are increased in the cochlear tissues, generating a toxic environment for the cells. Superoxide can react with nitric oxide and generate peroxynitrite. It can also be transformed into hydrogen peroxide, which can form, through catalysis by iron, the hydroxyl radical. Peroxynitrite and hydroxyl radical contribute to the degenerative process of cochlear structures.<sup><xref ref-type="bibr" rid="bibr5-0194599811426261">5</xref></sup></p>
<p>Erdosteine is a thiol derivative containing 2 sulfhydryl groups (-SH) that are released after hepatic first-pass metabolism. The 3 resulting metabolites possess pharmacologically active sulfhydryl groups and hence can act as free radical scavengers and antioxidants.<sup><xref ref-type="bibr" rid="bibr6-0194599811426261">6</xref>,<xref ref-type="bibr" rid="bibr7-0194599811426261">7</xref></sup> As a result of its antioxidant properties, erdosteine has been evaluated in vivo for various conditions, such as drug-induced nephrotoxicity,<sup><xref ref-type="bibr" rid="bibr8-0194599811426261">8</xref>-<xref ref-type="bibr" rid="bibr11-0194599811426261">11</xref></sup> drug-induced hepatotoxicity,<sup><xref ref-type="bibr" rid="bibr12-0194599811426261">12</xref></sup> ischemia/reperfusion injury,<sup><xref ref-type="bibr" rid="bibr13-0194599811426261">13</xref></sup> and drug-induced cardiotoxicity,<sup><xref ref-type="bibr" rid="bibr14-0194599811426261">14</xref></sup> and it is currently being employed as a mucolytic and antioxidant for chronic obstructive pulmonary disease.<sup><xref ref-type="bibr" rid="bibr5-0194599811426261">5</xref>,<xref ref-type="bibr" rid="bibr15-0194599811426261">15</xref></sup></p>
<p>The following study was designed to establish the protective effect of an intraperitoneal administration of erdosteine on cisplatin-induced ototoxicity in a guinea pig model.</p>
<sec id="section1-0194599811426261" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section2-0194599811426261">
<title>Animals</title>
<p>Healthy female albino Hartley guinea pigs (500-900 g) were used in the current study (Charles River Laboratory, Senneville, Quebec, Canada). The animals had free access to commercial food and water. They were kept under standard laboratory conditions: housed in a room at 20°C ± 4°C ambient temperature with a relative humidity of 50% ± 5% and a 12-hour light/dark cycle. The animals were kept in the animal care research facilities of The Montreal Children’s Hospital Research Institute. The study was approved and monitored by the Animal Care Committee in accordance with the Canadian Council of Animal Care guidelines.</p>
</sec>
<sec id="section3-0194599811426261">
<title>Experimental Design</title>
<p>The animals (27) were assigned to 4 groups, each receiving a different concentration of intraperitoneal erdosteine: group 1 (control group; n = 9) did not receive erdosteine, group 2 (n = 6) received 100 mg/kg/d, group 3 (n = 6) received 200 mg/kg/d, and group 4 (n = 6) received 500 mg/kg/d. The animals in the experimental groups received the erdosteine injection daily for 4 days. All of the animals received 12 mg/kg of intraperitoneal (IP) cisplatin on day 1. The dosage of cisplatin has been determined by previous research at our laboratory.<sup><xref ref-type="bibr" rid="bibr16-0194599811426261">16</xref></sup> It was demonstrated that this dose causes sufficient ototoxicity as a model yet very low mortality rates.</p>
</sec>
<sec id="section4-0194599811426261">
<title>Erdosteine and Cisplatin Treatment</title>
<p>The erdosteine injections were prepared by dissolving erdosteine (Haohua Industry, China) in sodium bicarbonate solution. Then, 0.9% NaCl was added to the mixture to obtain a total volume of 10 mL. Cisplatin (1 mg/mL; Hospira, Lake Forest, IL) was administered under anesthesia with isoflurane. A subcutaneous bolus of 10 mL sterile isotonic saline was injected daily for hydration, and supplements of hay were given for the duration of the experiment. The animals were monitored daily for signs of pain and weight loss. Animals were euthanized 72 hours following the cisplatin injection. Treatments and pre–auditory brainstem response (ABR) measurements were performed by the main author, and postmeasurements were evaluated by an external audiology reviewer blinded to the treatments administered.</p>
</sec>
<sec id="section5-0194599811426261">
<title>Auditory Brainstem Response</title>
<p>The ABR was performed prior to any injection (baseline measurement) and 72 hours following the cisplatin IP administration (postmeasurement) to determine the ABR threshold shifts (sound pressure level [SPL] dB). The hearing threshold was defined as the lowest intensity of stimulation that resulted in a clear, reproducible waveform. The tympanic membranes and external auditory canals were inspected prior to the ABR measurement using an operating microscope. Animals with preexisting hearing loss and/or any abnormality in the external or middle ear were excluded from the study. The active electrode was placed subcutaneously within the pinna of the tested ear, the reference electrode at the vertex, and the ground electrode on the pinna of the contralateral pinna. The ABR was measured at 4 frequencies (8, 16, 20, and 25 kHz) on the Smart EP device (Intelligent Hearing Systems, Miami, FL) using tone-burst stimulus with a rate of 39.1 bursts/s and alternating polarity. The response to the stimulus was averaged from 1600 sweeps. The measurements began at 80 dB and subsequently were decreased or increased by 20 dB and then 10 dB until the last 3 clear, reproducible waveforms were obtained. Threshold shifts were calculated by comparing the precisplatin and postcisplatin hearing threshold values.</p>
</sec>
<sec id="section6-0194599811426261">
<title>Scanning Electron Microscopy</title>
<p>Immediately following the post-ABR measurement, animals were euthanized and cochlear dissection was completed; cochleae were removed, dissected, and fixed in 2.5% glutaraldehyde for 2 hours. The cochleae were then left in 0.1 M phosphate buffer solution for 24 hours at 4°C. The specimens were postfixed in osmium tetroxide for ½ hours and later dehydrated in a series of ethanol solutions for 15 minutes each: 35%, 50%, and 70%. The cochleae were drilled until the covering bone became thin. The bone covering was then removed, and the organ of Corti was dissected. These samples were dehydrated in a series of ethanol solutions for 15 minutes each: 90%, 95%, and absolute ethanol followed by critical point drying, mounting on pin stubs, and sputter coated with gold. The samples were analyzed under a field emission scanning electron microscope (Hitachi S4700; Hitachi, Tokyo, Japan).</p>
</sec>
<sec id="section7-0194599811426261">
<title>Outer Hair Cell Counts</title>
<p>Outer hair cell (OHC) counts were performed for scanning electron microscopy samples of groups 1, 2, and 4. A modified version of a 4-grade scale for qualitative and quantitative evaluation of cochlear damage described previously<sup><xref ref-type="bibr" rid="bibr17-0194599811426261">17</xref></sup> was used: normal (N): OHC with normal stereocilia; grade 1: OHC with 10% to 50% damage or loss of stereocilia; grade 2: OHC with less than 50% of stereocilia remaining; grade 3: rupture of the cuticular plate and missing hair cells. The results are presented as the percentage of outer hair cells in each grade category for the apical, middle, and basal turns.</p>
</sec>
<sec id="section8-0194599811426261">
<title>Statistical Analysis</title>
<p>Differences between the 4 groups were evaluated with the use of the Kruskal-Wallis 1-way analysis, and the Wilcoxon rank-sum test was subsequently performed for further analysis between 2 groups. Statistical significance was set at <italic>P</italic> ≤ .05. The sample size for the experimental groups was calculated using the sample size calculator from the Department of Statistics of the University of British Columbia using the following criteria: power = 0.08, α = .05, σ = 15, µ1 = 0, and µ2 = 25. (<ext-link ext-link-type="uri" xlink:href="http://www.stat.ubc.ca/~rollin/stats/ssize/n2.html">http://www.stat.ubc.ca/~rollin/stats/ssize/n2.html</ext-link>).</p>
</sec>
</sec>
<sec id="section9-0194599811426261" sec-type="results">
<title>Results</title>
<sec id="section10-0194599811426261">
<title>Auditory Brainstem Response</title>
<p>Animals in the control group demonstrated a large hearing loss, presenting mean ABR threshold shifts of 55 dB at 8 kHz, 51 dB at 16 kHz, 42 dB at 20 kHz, and 46 dB at 25 kHz (<xref ref-type="fig" rid="fig1-0194599811426261"><bold>Figure 1</bold></xref>). A dose of 12 mg/kg of intraperitoneal cisplatin caused evident ototoxicity in the guinea pigs. Animals exposed to cisplatin and the lowest concentration of erdosteine (100 mg/kg) too showed marked ototoxicity and no data to support otoprotection. On the other hand, animals exposed to cisplatin and higher concentrations of erdosteine, 200 mg/kg and 500 mg/kg, demonstrated significant otoprotection at 25 kHz, with a <italic>P</italic> value of .004, median value of 27.5, and confidence interval of (10.95, 42.38) for group 3 and <italic>P</italic> value of .003, median of 23, and confidence interval of (10.07, 34.10) for group 4. The highest dose also showed significant difference as compared with the control group at 20 kHz with a <italic>P</italic> value of .036, median of 26.0, and confidence interval (−0.16, 41.59; <xref ref-type="table" rid="table1-0194599811426261"><bold>Table 1</bold></xref>).</p>
<fig id="fig1-0194599811426261" position="float">
<label>Figure 1.</label>
<caption><p>Auditory brainstem response shifts in decibels (mean ± SEM) for cisplatin- and cisplatin plus erdosteine–treated guinea pigs. Threshold shifts were calculated by subtracting baseline measurements from postmeasurements. Statistically significant differences were observed at the 20-kHz frequency with 500 mg/kg of erdosteine and at the 25-kHz frequency for the groups treated with 200 mg/kg and 500 mg/kg. * <italic>P</italic> &lt; .05.</p></caption>
<graphic xlink:href="10.1177_0194599811426261-fig1.tif"/>
</fig>
<table-wrap id="table1-0194599811426261" position="float">
<label>Table 1.</label>
<caption><p>Statistical Analysis</p></caption>
<graphic alternate-form-of="table1-0194599811426261" xlink:href="10.1177_0194599811426261-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="6">Kruskal-Wallis Test</th>
</tr>
<tr>
<th/>
<th/>
<th align="center" colspan="4">ABR Threshold Shifts<sup><xref ref-type="table-fn" rid="table-fn1-0194599811426261">a</xref></sup> (95% Confidence Interval)</th>
</tr>
<tr>
<th align="left">Frequency, kHz</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Group 1</th>
<th align="center">Group 2</th>
<th align="center">Group 3</th>
<th align="center">Group 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>.245</td>
<td>55</td>
<td>68</td>
<td>39</td>
<td>37.5</td>
</tr>
<tr>
<td/>
<td/>
<td>(31.99, 77.34)</td>
<td>(29.12, 105.90)</td>
<td>(14.52, 63.82)</td>
<td>(12.06, 62.94)</td>
</tr>
<tr>
<td>16</td>
<td>.067</td>
<td>51</td>
<td>67</td>
<td>41</td>
<td>32.75</td>
</tr>
<tr>
<td/>
<td/>
<td>(37.26, 64.74)</td>
<td>(48.72, 85.44)</td>
<td>(15.31, 66.36)</td>
<td>(8.91, 56.60)</td>
</tr>
<tr>
<td>20</td>
<td>.026<sup><xref ref-type="table-fn" rid="table-fn2-0194599811426261">b</xref></sup></td>
<td>42</td>
<td>53</td>
<td>34</td>
<td>20.9</td>
</tr>
<tr>
<td/>
<td/>
<td>(31.89, 51.78)</td>
<td>(37.58, 68.75)</td>
<td>(13.65, 53.83)</td>
<td>(-0.16, 41.59)</td>
</tr>
<tr>
<td>25</td>
<td>.011<sup><xref ref-type="table-fn" rid="table-fn2-0194599811426261">b</xref></sup></td>
<td>46</td>
<td>41</td>
<td>27</td>
<td>22.1</td>
</tr>
<tr>
<td/>
<td/>
<td>(37.79, 54.66)</td>
<td>(31.06, 50.60)</td>
<td>(10.95, 42.38)</td>
<td>(10.07, 34.10)</td>
</tr>
<tr>
<th align="left" colspan="6">Wilcoxon Rank-Sum Test</th>
</tr>
<tr>
<td>20 kHz</td>
<td><italic>P</italic> Value</td>
<td>Median</td>
<td>25 kHz</td>
<td><italic>P</italic> Value</td>
<td>Median</td>
</tr>
<tr>
<td>Groups 1-2</td>
<td>.114</td>
<td>Group 1: 42.0</td>
<td>Groups 1-2</td>
<td>.456</td>
<td>Group 1: 49.0</td>
</tr>
<tr>
<td>Groups 1-3</td>
<td>.456</td>
<td>Group 2: 58.5</td>
<td>Groups 1-3</td>
<td>.004<sup><xref ref-type="table-fn" rid="table-fn2-0194599811426261">b</xref></sup></td>
<td>Group 2: 36.3</td>
</tr>
<tr>
<td>Groups 1-4</td>
<td>.036<sup><xref ref-type="table-fn" rid="table-fn2-0194599811426261">b</xref></sup>
</td>
<td>Group 3: 36.3</td>
<td>Groups 1-4</td>
<td>.003<sup><xref ref-type="table-fn" rid="table-fn2-0194599811426261">b</xref></sup></td>
<td>Group 3: 28.0</td>
</tr>
<tr>
<td/>
<td/>
<td>Group 4: 26.0</td>
<td/>
<td/>
<td>Group 4: 23.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599811426261">
<label>a</label>
<p>Values in sound pressure level dB.</p>
</fn>
<fn id="table-fn2-0194599811426261">
<label>b</label>
<p><italic>P</italic> value &lt;.05</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0194599811426261">
<title>Scanning Electron Microscopy: OHC Counts</title>
<p>Animals receiving cisplatin IP only (group 1) presented damage throughout the cochlea, with a greater percentage of cells being assigned to grade 3. Greater injury was observed in the basal turn of the cochlea. Few cells were included in grades 1 and 2. Animals that received 100 mg/kg of erdosteine IP presented hair cell counts in a similar pattern to group 1, and no statistically significant difference in hair cell counts was observed in this group. Cochleae dissected from group 4, receiving 500 mg/kg of erdosteine IP, presented a greater number of cells assigned to grade 1 and a decrease in the percentage of cells in grade 3 (<xref ref-type="fig" rid="fig2-0194599811426261"><bold>Figure 2</bold></xref>). Statistically significant decreases in OHC counts assigned to grade 3 were observed for the middle and basal turn of the cochleae in this group (<xref ref-type="table" rid="table2-0194599811426261"><bold>Table 2</bold></xref>).</p>
<fig id="fig2-0194599811426261" position="float">
<label>Figure 2.</label>
<caption><p>Scanning electron microscopy. Scanning electron microscopy of outer hair cells in basal turn of the cochlea. (A) Normal. (B) Cisplatin (group 1). (C) Cisplatin + erdosteine 100 mg/kg (group 2). (D) Cisplatin + erdosteine 500 mg/kg (group 3). Outer hair cells observed in group 4 present a greater preservation of stereocilia as compared with cisplatin-treated animals.</p></caption>
<graphic xlink:href="10.1177_0194599811426261-fig2.tif"/>
</fig>
<table-wrap id="table2-0194599811426261" position="float">
<label>Table 2.</label>
<caption><p>Outer Hair Cell Counts and Grading</p>
</caption>
<graphic alternate-form-of="table2-0194599811426261" xlink:href="10.1177_0194599811426261-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Grade</th>
<th align="center">N</th>
<th align="center">1</th>
<th align="center">2</th>
<th align="center">3</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Normal</td>
</tr>
<tr>
<td> Apex</td>
<td>100 ± 0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> Middle</td>
<td>100 ± 0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> Base</td>
<td>100 ± 0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td colspan="5">Cisplatin</td>
</tr>
<tr>
<td> Apex</td>
<td>84.4 ± 2.9</td>
<td>0.5 ± 0.7</td>
<td>1.9 ± 2.7</td>
<td>13.2 ± 1.0</td>
</tr>
<tr>
<td> Middle</td>
<td>71.7 ± 9.8</td>
<td>3.0 ± 4.2</td>
<td>4.0 ± 4.2</td>
<td>22.5 ± 1.5</td>
</tr>
<tr>
<td> Base</td>
<td>63.3 ± 7.6</td>
<td>0</td>
<td>8.1 ± 7.9</td>
<td>28.6 ± 0.3</td>
</tr>
<tr>
<td colspan="5">Cisplatin + erdosteine 100 mg/kg</td>
</tr>
<tr>
<td> Apex</td>
<td>91.0 ± 4.8</td>
<td>0</td>
<td>0</td>
<td>9.1 ± 4.9</td>
</tr>
<tr>
<td> Middle</td>
<td>78.3 ± 1.7</td>
<td>1.1 ± 1.5</td>
<td>0</td>
<td>20.7 ± 0.2</td>
</tr>
<tr>
<td> Base</td>
<td>70.8 ± 5.6</td>
<td>1.9 ± 3.9</td>
<td>0.5 ± 1.1</td>
<td>26.8 ± 8.4</td>
</tr>
<tr>
<td colspan="5">Cisplatin + erdosteine 500 mg/kg</td>
</tr>
<tr>
<td> Apex</td>
<td>87.9 ± 9.7</td>
<td>1.0 ± 2.3</td>
<td>0</td>
<td>11.1 ± 8.6</td>
</tr>
<tr>
<td> Middle</td>
<td>90.9 ± 10.1</td>
<td>0.6 ± 1.2</td>
<td>0.3 ± 1.0</td>
<td>8.1 ± 9.3<sup><xref ref-type="table-fn" rid="table-fn4-0194599811426261">a</xref></sup></td>
</tr>
<tr>
<td> Base</td>
<td>89.7 ± 8.7</td>
<td>0.8 ± 2.3</td>
<td>0.8 ± 2.4</td>
<td>8.6 ± 6.9<sup><xref ref-type="table-fn" rid="table-fn4-0194599811426261">a</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0194599811426261">
<p>Abbreviation: N, normal.</p>
</fn>
<fn id="table-fn4-0194599811426261">
<label>a</label>
<p><italic>P</italic> value ≤.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-0194599811426261" sec-type="discussion">
<title>Discussion</title>
<p>These findings support the fact that thiol derivatives such as erdosteine provide protection against oxidative stress caused by cisplatin. Cisplatin induces superoxide production in cochlear tissues, which react with nitric oxide to form peroxynitrite, a toxic radical capable of activating the apoptotic cascade through caspase-3.<sup><xref ref-type="bibr" rid="bibr2-0194599811426261">2</xref></sup> Erdosteine is activated by first-pass metabolism generating Met I, the pharmacologically active metabolite containing an active sulfhydryl group.<sup><xref ref-type="bibr" rid="bibr7-0194599811426261">7</xref></sup> It has been observed that Met I is capable of reacting with reactive oxygen species, nitric oxide, and nitric oxide–derived peroxynitrite and furthermore has both antioxidant and scavenging activities.<sup><xref ref-type="bibr" rid="bibr18-0194599811426261">18</xref></sup> Erdosteine has been shown to provide protection against cisplatin-induced nephrotoxicity<sup><xref ref-type="bibr" rid="bibr11-0194599811426261">11</xref>,<xref ref-type="bibr" rid="bibr19-0194599811426261">19</xref>-<xref ref-type="bibr" rid="bibr21-0194599811426261">21</xref></sup> and cisplatin-induced hepatic oxidant injury<sup><xref ref-type="bibr" rid="bibr22-0194599811426261">22</xref></sup> when given orally.</p>
<p>One previous study evaluated the potential protective effect of erdosteine on cisplatin-induced ototoxicity in a rat model. Erdosteine was administered orally, and hearing loss was evaluated with distortion product otoacoustic emissions (DPOAEs). The authors observed significant protection on cochlear function as measured by DPOAEs.<sup><xref ref-type="bibr" rid="bibr23-0194599811426261">23</xref></sup> In this study, we demonstrate that an intraperitoneal administration of erdosteine provides otoprotection as observed by ABR measurements and OHC counts by scanning electron microscopy. Limitations of the study include the lack of enzymatic activity detection for the main antioxidant enzymes of the inner ear. Catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase are important modulators of the oxidative stress response of the cochlea.<sup><xref ref-type="bibr" rid="bibr2-0194599811426261">2</xref></sup> Furthermore, the number of animals per experimental group was minimal. A larger study would provide greater insight. Additional studies are required to determine dosage and interference with cisplatin oncology regimens.</p>
</sec>
<sec id="section13-0194599811426261" sec-type="conclusions">
<title>Conclusion</title>
<p>A systemic administration of erdosteine seems to be a promising future therapeutic strategy for cisplatin-induced ototoxicity, as observed by the changes in hearing thresholds and OHC counts.</p>
</sec>
<sec id="section14-0194599811426261">
<title>Author Contributions</title>
<p><bold>Sofia Waissbluth</bold>, acquired data (ABR and scanning electron microscopy), analyzed data (ABR and scanning electron microscopy cell counts), drafted the article, and approved final version of article to be published; <bold>Isabelle Dupuis</bold>, acquired data (ABR), analyzed data (ABR), revised the article, and approved final version of article to be published; <bold>Sam J. Daniel</bold>, corresponding author, designed the study, revised the article, and approved final version of article to be published.</p>
</sec>
<sec id="section15-0194599811426261">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> Sam J. Daniel is a speaker at Abbott and is on the advisory board at Merck.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> Canadian Institute of Health Research. Role: none.</p>
</sec>
</body>
<back>
<ack>
<p>The authors wish to thank Line Mongeon from the Department of Biomedical Engineering at the McGill University Health Center for her invaluable technical assistance.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599811426261">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rybak</surname><given-names>LP</given-names></name>
</person-group>. <article-title>Mechanisms of cisplatin ototoxicity and progress in otoprotection</article-title>. <source>Curr Opin Otolaryngol Head Neck Surg</source>. <year>2007</year>;<volume>15</volume>:<fpage>364</fpage>-<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr2-0194599811426261">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rybak</surname><given-names>LP</given-names></name>
<name><surname>Whitworth</surname><given-names>CA</given-names></name>
<name><surname>Mukherjea</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Mechanisms of cisplatin-induced ototoxicity and prevention</article-title>. <source>Hear Res</source>. <year>2007</year>;<volume>226</volume>:<fpage>157</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr3-0194599811426261">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clerici</surname><given-names>WJ</given-names></name>
<name><surname>Hensley</surname><given-names>K</given-names></name>
<name><surname>DiMartino</surname><given-names>DL</given-names></name>
<etal/></person-group>. <article-title>Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants</article-title>. <source>Hear Res</source>. <year>1996</year>;<volume>98</volume>:<fpage>116</fpage>-<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr4-0194599811426261">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rybak</surname><given-names>LP</given-names></name>
<name><surname>Husain</surname><given-names>K</given-names></name>
<name><surname>Morris</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Effect of protective agents against cisplatin ototoxicity</article-title>. <source>Am J Otol</source>. <year>2000</year>;<volume>21</volume>:<fpage>513</fpage>-<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr5-0194599811426261">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JE</given-names></name>
<name><surname>Nakagawa</surname><given-names>T</given-names></name>
<name><surname>Kim</surname><given-names>TS</given-names></name>
<etal/>
</person-group>. <article-title>Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment</article-title>. <source>Acta Otolaryngol</source>. <year>2004</year>;<volume>124</volume>:<fpage>1131</fpage>-<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr6-0194599811426261">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dechant</surname><given-names>KL</given-names></name>
<name><surname>Noble</surname><given-names>S.</given-names></name>
</person-group> <article-title>Erdosteine</article-title>. <source>Drugs</source>. <year>1996</year>;<volume>52</volume>:<fpage>875</fpage>-<lpage>881</lpage>.</citation>
</ref>
<ref id="bibr7-0194599811426261">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braga</surname><given-names>PC</given-names></name>
<name><surname>Culici</surname><given-names>M</given-names></name>
<name><surname>Dal Sasso</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Free radical scavenging activity of erdosteine metabolite I investigated by electron paramagnetic resonance spectroscopy</article-title>. <source>Pharmacology</source>. <year>2010</year>;<volume>85</volume>:<fpage>195</fpage>-<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr8-0194599811426261">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kandis</surname><given-names>H</given-names></name>
<name><surname>Erkan</surname><given-names>ME</given-names></name>
<name><surname>Yildirim</surname><given-names>U</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of the effects of N-acetyl cysteine and erdosteine in rats with renal injury caused by paracetamol intoxication</article-title>. <source>Hum Exp Toxicol</source>. <year>2011</year>:<volume>30</volume>:<fpage>1350</fpage>-<lpage>1358</lpage>.</citation>
</ref>
<ref id="bibr9-0194599811426261">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oktar</surname><given-names>S</given-names></name>
<name><surname>Gökçe</surname><given-names>A</given-names></name>
<name><surname>Aydin</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice</article-title>. <source>Toxicol Ind Health</source>. <year>2010</year>;<volume>26</volume>:<fpage>433</fpage>-<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr10-0194599811426261">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cabuk</surname><given-names>M</given-names></name>
<name><surname>Gurel</surname><given-names>A</given-names></name>
<name><surname>Sen</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Renoprotective effect of erdosteine in rats against gentamicin nephrotoxicity: a comparison of 99mTc-DMSA uptake with biochemical studies</article-title>. <source>Mol Cell Biochem</source>. <year>2008</year>;<volume>308</volume>:<fpage>35</fpage>-<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr11-0194599811426261">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ozyurt</surname><given-names>H</given-names></name>
<name><surname>Yildirim</surname><given-names>Z</given-names></name>
<name><surname>Kotuk</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner</article-title>. <source>J Appl Toxicol</source>. <year>2004</year>;<volume>24</volume>:<fpage>269</fpage>-<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr12-0194599811426261">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erarslan</surname><given-names>E</given-names></name>
<name><surname>Ekiz</surname><given-names>F</given-names></name>
<name><surname>Uz</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Effects of erdosteine on cyclosporine-A-induced hepatotoxicity in rats</article-title>. <source>Drug Chem Toxicol</source>. <year>2011</year>;<volume>34</volume>:<fpage>32</fpage>-<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr13-0194599811426261">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JY</given-names></name>
<name><surname>Kim</surname><given-names>HS</given-names></name>
<name><surname>Park</surname><given-names>CS</given-names></name>
<etal/>
</person-group>. <article-title>Erdosteine in renal ischemia-reperfusion injury: an experimental study in pigs</article-title>. <source>J Vet Med Sci</source>. <year>2010</year>;<volume>72</volume>:<fpage>127</fpage>-<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr14-0194599811426261">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Selcoki</surname><given-names>Y</given-names></name>
<name><surname>Uz</surname><given-names>E</given-names></name>
<name><surname>Bayrak</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats</article-title>. <source>Toxicology</source>. <year>2007</year>;<volume>239</volume>:<fpage>53</fpage>-<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr15-0194599811426261">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cazzola</surname><given-names>M</given-names></name>
<name><surname>Floriani</surname><given-names>I</given-names></name>
<name><surname>Page</surname><given-names>CP</given-names></name>
</person-group>. <article-title>The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data</article-title>. <source>Pulm Pharmacol Ther</source>. <year>2010</year>;<volume>23</volume>:<fpage>135</fpage>-<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr16-0194599811426261">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>D</given-names></name>
<name><surname>Daniel</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2011</year>;<volume>145</volume>:<fpage>452</fpage>-<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr17-0194599811426261">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saito</surname><given-names>T</given-names></name>
<name><surname>Manabe</surname><given-names>Y</given-names></name>
<name><surname>Honda</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Semiquantitative analysis by scanning electron microscopy of cochlear hair cell damage by ototoxic drugs</article-title>. <source>Scanning Microsc</source>. <year>1995</year>;<volume>9</volume>:<fpage>271</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr18-0194599811426261">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dal Sasso</surname><given-names>M</given-names></name>
<name><surname>Culici</surname><given-names>M</given-names></name>
<name><surname>Bianchi</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Inhibitory effects of metabolite I of erdosteine on the generation of nitric oxide and peroxynitrite chemiluminescence by human neutrophils</article-title>. <source>Pharmacology</source>. <year>2004</year>;<volume>71</volume>:<fpage>120</fpage>-<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr19-0194599811426261">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yilmaz</surname><given-names>HR</given-names></name>
<name><surname>Iraz</surname><given-names>M</given-names></name>
<name><surname>Sogut</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats</article-title>. <source>Pharmacol Res</source>. <year>2004</year>;<volume>50</volume>:<fpage>287</fpage>-<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr20-0194599811426261">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yildirim</surname><given-names>Z</given-names></name>
<name><surname>Sogut</surname><given-names>S</given-names></name>
<name><surname>Odaci</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats</article-title>. <source>Pharmacol Res</source>. <year>2003</year>;<volume>47</volume>:<fpage>149</fpage>-<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr21-0194599811426261">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Söğüt</surname><given-names>S</given-names></name>
<name><surname>Kotuk</surname><given-names>M</given-names></name>
<name><surname>Yilmaz</surname><given-names>HR</given-names></name>
<etal/>
</person-group>. <article-title>In vivo evidence suggesting a role for purine-catabolizing enzymes in the pathogenesis of cisplatin-induced nephrotoxicity in rats and effect of erdosteine against this toxicity</article-title>. <source>Cell Biochem Funct</source>. <year>2004</year>;<volume>22</volume>:<fpage>157</fpage>-<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr22-0194599811426261">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koc</surname><given-names>A</given-names></name>
<name><surname>Duru</surname><given-names>M</given-names></name>
<name><surname>Ciralik</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats</article-title>. <source>Mol Cell Biochem</source>. <year>2005</year>;<volume>278</volume>:<fpage>79</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr23-0194599811426261">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kalcioglu</surname><given-names>MT</given-names></name>
<name><surname>Kizilay</surname><given-names>A</given-names></name>
<name><surname>Gulec</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>The protective effect of erdosteine against ototoxicity induced by cisplatin in rats</article-title>. <source>Eur Arch Otorhinolaryngol</source>. <year>2005</year>;<volume>262</volume>:<fpage>856</fpage>-<lpage>863</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>